Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events — Christopher A. Muir (2022) | RDL Network
Association of Antithyroid Antibodies in Checkpoint Inhibitor–Associated Thyroid Immune–Related Adverse Events
Article 2022 en
Authors
CM
Christopher A. Muir
CW
Cameron Wood
RC
Roderick Clifton‐Bligh
Abstract
1 min read
TPOAb and TgAb positivity at baseline was more prevalent in patients who developed thyroid irAEs. Statistically significant increases or new antibody positivity was observed in association with overt thyrotoxicosis. TPOAb and TgAb positivity or increases during ICI treatment may be a useful biomarker to identify patients at increased risk of thyroid irAEs, particularly overt thyrotoxicosis.
Linda Wu, John M. Wentworth, Christopher Liddle, Nicole Fewings, Matteo S. Carlino, David A. Brown, Roderick Clifton‐Bligh, Georgina V. Long, Richard A Scolyer, Nicholas Norris, Sarah C. Sasson, Venessa Tsang, Alexander M. Menzies, Jenny E. Gunton
Rebecca Simpson, Erin R. Shanahan, Inês Pires da Silva, Irene L. M. Reijers, Judith M. Versluis, Alexander M. Menzies, Gonzalez Maria, Umaimainthan Palendira, James S. Wilmott, Christian U. Blank, Richard A Scolyer, Georgina V. Long
Justin M. Balko, Lydia Yao, Siwei Zhang, Catherine C. Fahey, Alexandra M. Haugh, Andrea L. Davis, Eric Mukherjee, Christian Hammer, Elizabeth J. Phillips, Adrian Bejan, Yaomin Xu, Douglas B. Johnson
Discussion(0)
No comments yet. Be the first to comment.